GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (ASX:IMC) » Definitions » Total Receivables

Immuron (ASX:IMC) Total Receivables : A$1.39 Mil (As of Jun. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Immuron Total Receivables?

Immuron's Total Receivables for the quarter that ended in Jun. 2024 was A$1.39 Mil.


Immuron Total Receivables Historical Data

The historical data trend for Immuron's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Total Receivables Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.34 0.66 0.42 1.39

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.34 0.42 0.56 1.39

Immuron Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Immuron Total Receivables Related Terms

Thank you for viewing the detailed overview of Immuron's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron Headlines

No Headlines